Back to Trades
Total Value
$12.4M
Net $12.4M bought
Filing Date
Jul 20, 2026
1 transaction
Purchases
$12.4M
1 transaction
Trade Summary
On Jul 16, 2026, Fairmount Funds Management LLC, Director, 10% Owner, purchased $12.4M of CRESCENT BIOPHARMA, INC. (CBIO) across 1 transaction. The filing covers Ordinary Shares and reflects net buying of $12.4M. Reported prices ranged from $0.00 to $14.50. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- CRESCENT BIOPHARMA, INC.
- Ticker Symbol
- CBIO
- CIK
- 0001253689
Insider Information
- Role
- Director, 10% Owner
- Location
- WEST CONSHOHOCKEN, PA
Filing Details
- Filing Date
- Jul 20, 2026
- Transaction Date
- Jul 16, 2026
- Accession Number
- 0001104659-26-085113
- Form Type
- 4
- Net Trading Amount
- $12.4M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 16, 2026 | Ordinary Shares | 853,450 | $14.50 | Purchase | $12.4M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 16, 2026 | CBIO derivative | 525,897 | $0.00 | Purchase | $526 |
Want live alerts when Fairmount Funds Management LLC trades again?
Download Insider Trades to track CBIO, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- (F2)The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of outstanding shares of common stock of the Issuer immediately after giving effect to such exercise.